Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 studyLuca Gianni, Giuseppe Viale, Mauro Mansutti et al.|The Lancet Oncology|2018Cited by 174
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trialLucia Del Mastro, Paolo Bruzzi, Mauro Mansutti et al.|The Lancet Oncology|2021Cited by 86
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancerLuca Gianni, Giuseppe Viale, Marco Colleoni et al.|npj Breast Cancer|2022Cited by 29
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studiesMatteo Lambertini, Lucia Del Mastro, Eva Blondeaux et al.|EClinicalMedicine|2023Cited by 28
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozoleGianluigi Lunardi, Lucia Del Mastro, Patrizia Piccioli et al.|Breast Cancer Research and Treatment|2012Cited by 23